4anm

<StructureSection load='4anm' size='340' side='right' caption='[[4anm]], [[Resolution|resolution]] 1.70&Aring;' scene=''>

<table><tr><td colspan='2'>[[4anm]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Zea_mays Zea mays]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ANM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ANM FirstGlance]. <br>

</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=WUL:8-BROMANYL-2-[[(3S)-3-OXIDANYLPYRROLIDIN-1-YL]METHYL]-3H-[1]BENZOFURO[3,2-D]PYRIMIDIN-4-ONE'>WUL</scene><br>

<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1daw|1daw]], [[1day|1day]], [[1ds5|1ds5]], [[1f0q|1f0q]], [[1j91|1j91]], [[1jam|1jam]], [[1lp4|1lp4]], [[1lpu|1lpu]], [[1lr4|1lr4]], [[1m2p|1m2p]], [[1m2q|1m2q]], [[1m2r|1m2r]], [[1om1|1om1]], [[1zoe|1zoe]], [[1zog|1zog]], [[1zoh|1zoh]]</td></tr>

<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>

<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4anm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4anm OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4anm RCSB], [http://www.ebi.ac.uk/pdbsum/4anm PDBsum]</span></td></tr>

<table>

<div style="background-color:#fffaf0;">

== Publication Abstract from PubMed ==

CDC7 is a serine/threonine kinase that has been shown to be required for the initiation and maintenance of DNA replication. Up-regulation of CDC7 is detected in multiple tumor cell lines, with inhibition of CDC7 resulting in cell cycle arrest. In this paper, we disclose the discovery of a potent and selective CDC7 inhibitor, XL413 (14), which was advanced into Phase 1 clinical trials. Starting from advanced lead 3, described in a preceding communication, we optimized the CDC7 potency and selectivity to demonstrate in vitro CDC7 dependent cell cycle arrest and in vivo tumor growth inhibition in a Colo-205 xenograft model.

 

Discovery of XL413, a potent and selective CDC7 inhibitor.,Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. Epub 2012 Apr 16. PMID:22560567<ref>PMID:22560567</ref>

 

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

*[[Casein kinase|Casein kinase]]

[[Category: Non-specific serine/threonine protein kinase]]

[[Category: Stout, T J.]]

[[Category: Transferase]]